Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol, Antipsychotic Agents, Central Nervous System Diseases, Clinical Therapy, Olanzapine, Quetiapine
Conditions
Keywords
Schizophrenia, Metabolic Syndrome, Flupentixol, olanzapine, quetiapine, Central Nervous System Diseases, Clinical Therapy, Antipsychotic Agents
Brief summary
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients. This study is the first clinical trial to explore the treatment of patients with flupentixol combined with MARTAs. However, due to research limitations, the number of patients who participated in the clinical trial is small, and it depends on subsequent larger-scale clinical trials for more in-depth verification.
Detailed description
Objectives The effects of adjunctive Fute (Flupentixol) with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) on the metabolic profiles of patients and clinical efficacy of treatment in schizophrenia. Methodology It is expected to be admitted to patients with schizophrenia who are over 20 years old and are being treated with MARTAs antipsychotics due to poor treatment efficacy or significant weight gain after use, poor blood sugar control, and other metabolic syndrome-related problems, but Patients who do not meet the medication standards for diabetes or hyperlipidemia, and are willing to accept additional use of Flupentixol after evaluation by the physician. To compare whether the original MARTAs dose can be effectively reduced after additional use of Flupentixol for at least 12 weeks, whether the symptoms of psychosis have improved, and whether the various factors of metabolic syndrome have improved. Number of patients It is estimated that 30 subjects will be recruited to participate in this clinical trial. This report is an interim report with the results of 15 subjects. Diagnosis and main criteria for inclusion Patients suffering from schizophrenia who are over 20 years old and are using MARTAs antipsychotics. Test product, dose and mode of administration, batch number Fute F.C. Tablets (Flupentixol), the clinically recommended dosage should be adjusted according to the individual conditions of the patients. Generally speaking, a low dose should be administered at the beginning. Then the dosage is increased according to the treatment response to achieve the appropriate curative effect as soon as possible. The maintenance dose is usually administered as a single dose in the morning, and the maintenance dose is usually 5-20 mg/day. The initial dose is 3-15 mg/day, divided into 2-3 administrations, and can be increased to 40 mg/day if necessary.
Interventions
DRUGFlupentixol
Flupentixol tablets are indicated for: • maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity.
DRUGMulti-acting receptor-targeted antipsychotics (MARTAs)
Multi-acting receptor-targeted antipsychotics (MARTAs)
Sponsors
Taichung Veterans General Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
It is expected to be admitted to patients with schizophrenia who are over 20 years old and are being treated with MARTAs antipsychotics due to poor treatment efficacy or significant weight gain after use, poor blood sugar control, and other metabolic syndrome-related problems, but Patients who do not meet the medication standards for diabetes or hyperlipidemia, and are willing to accept additional use of Flupentixol after evaluation by the physician. To compare whether the original MARTAs dose can be effectively reduced after additional use of Flupentixol for at least 12 weeks, whether the symptoms of psychosis have improved, and whether the various factors of metabolic syndrome have improved.
Intervention model description
It is expected to be admitted to patients with schizophrenia who are over 20 years old and are being treated with MARTAs antipsychotics due to poor treatment efficacy or significant weight gain after use, poor blood sugar control, and other metabolic syndrome-related problems, but Patients who do not meet the medication standards for diabetes or hyperlipidemia, and are willing to accept additional use of Flupentixol after evaluation by the physician. To compare whether the original MARTAs dose can be effectively reduced after additional use of Flupentixol for at least 12 weeks, whether the symptoms of psychosis have improved, and whether the various factors of metabolic syndrome have improved.
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients who suffer from schizophrenia are over 20 years old and are using MARTAs antipsychotics.
Exclusion criteria
* \>65y aged Patients. * \>Other non-schizophrenia disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Global Impression-Severity scale (CGI-S) | 12 weeks | The clinical efficacy of schizophrenia, Clinical Global Impression-Severity scale (CGI-S), in patients taking MARTAs combined with Flupentixol for 12 weeks. The CGI provides an overall clinician-determined summary measure that takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function. CGI-Severity (CGI-S) which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days. |
| Positive and Negative Syndrome Scale (PANSS) | 12 weeks | The clinical efficacy of schizophrenia, Positive and Negative Syndrome Scale (PANSS), in patients taking MARTAs combined with Flupentixol for 12 weeks. PANSS is a medical scale used for measuring symptom severity of patients with schizophrenia. It is widely used in the study of antipsychotic therapy. The scale is known as the gold standard that all assessments of psychotic behavioral disorders should follow. The name refers to the two types of symptoms in schizophrenia, as defined by the American Psychiatric Association: positive symptoms, which refer to an excess or distortion of normal functions (e.g., hallucinations and delusions), and negative symptoms, which represent a diminution or loss of normal functions. Some of these functions which may be lost include normal thoughts, actions, ability to tell fantasies from reality, and the ability to properly express. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| High-density lipoprotein (HDL) cholesterol in mg/dL | 12 weeks | Metabolic syndrome-related factors in patients, high-density lipoprotein (HDL) cholesterol in mg/dL |
| Low-density lipoprotein (LDL) cholesterol in mg/dL | 12 weeks | Metabolic syndrome-related factors in patients, low-density lipoprotein (LDL) cholesterol in mg/dL |
| Blood creatinine in mg/dL | 12 weeks | Metabolic syndrome-related factors in patients, blood creatinine in mg/dL |
| Fasting blood glucose (FBG) in mg/dL | 12 weeks | Metabolic syndrome-related factors in patients, fasting blood glucose in mg/dL |
| Glutamine transaminase (r-GT) in U/L | 12 weeks | Metabolic syndrome-related factors in patients, glutamine transaminase (r-GT) in U/L |
| Aspartate transaminase (GOT) in U/L | 12 weeks | Metabolic syndrome-related factors in patients, aspartate transaminase (GOT) in U/L |
| Alanine transaminase (GPT) in U/L | 12 weeks | Metabolic syndrome-related factors in patients, alanine transaminase (GPT) in U/L |
| Triglyceride in mg/dL | 12 weeks | Metabolic syndrome-related factors in patients, triglyceride in mg/dL |
| Cholesterol in mg/dL | 12 weeks | Metabolic syndrome-related factors in patients, cholesterol in mg/dL |
Countries
Taiwan
Outcome results
None listed